Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 9, 2007, Pages 1126-1129

  Lin, X ^a   Gao, E S ^a   Li, D ^b   Zhang, M ^b   Dou, L X ^a   Yuan, W ^a  

^a SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^b Huangpu Maternal and Child Health Center   (China)

Author keywords

Intrauterine device; Menstrual blood loss; Tranexamic acid; Transamin

Indexed keywords

HEMATIN; PLACEBO; TRANEXAMIC ACID;

ADULT; ARTICLE; CHINESE; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADULT; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAUTERINE DEVICES; MENORRHAGIA; PROSPECTIVE STUDIES; TIME FACTORS; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 34548329740     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701516777     Document Type: Article

References (25)

1. Wu T, Buck G. Side effects and discontinuation rates of intrauterine contraceptive devices use in the Jilin Province of China [J]. Asia Pac J Pubic Health. 1998;10(1):33-8.
2. Stanback J, Grimes D. Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit? A multivariate analysis. Contraception. 1998;58(6):357-60.
3. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999;60(3):155-60.
4. Petta CA, Faundes D, Pimentel E, Diaz J, Bahamondes L. The use of vaginal ultrasound to identify copper T IUDs at high risk of expulsion. Contraception. 1996;54(5):287-9.
5. Batar I, Kuukankorpi A, Siljander M, Elomaa K, Rauramo I. Five-year clinical experiences with NOVA T 380 copper IUD. Contraception. 2002;66(5):309-14.
6. Neuteboom K, de Kroon CD, Dersjant-Roorda M, Jansen FW. Follow-up visits after IUD-insertion: sense or nosense? A technology assessment study to analyze the effectiveness of follow-up visits after insertion. Contraception. 2003;68(2):101-4.
7. Colli E, Tong D, Penhallegon R, Parazzini F. Reasons for contraceptive discontinuation in women 20-39 years old in New Zealand. Contraception. 1999;59(4):227-31.
8. Hefnawi F, Saleh A, Kandil O, El-Sheikha Z, Hassanein M, Askalani H. Fibrinolytic activity of menstrual blood in normal and menorrhagic women and in women wearing the Lippes Loop and the Cu-T (200). Int J Gynaecol Obstet. 1979;16(5):400-7.
9. Shaw ST, Macaulay LK, Sun NC, Tanaka MS, Roche PC. Changes of plasminogen activator in human uterine tissue induced by intrauterine contraceptive devices. Contraception. 1983;27(2):131-40.
10. Zhang PC, Fan RQ, Chen XM. Changes of peroxidase, plasminogen and fibrinolytic activity on menorrhagia induced by IUDS and the effect of treatment with vitamin E. Shengzhi Yu Biyun. 1987;7(3):59-61.
11. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;(4):CD000249.
12. Ewenstein BM. The pathophysiology of bleeding disorders presenting as abnormal uterine bleeding. Am J Obstet Gynecol. 1996;175(3 Pt 2):770-7.
13. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003;63(13):1417-33.
14. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879-83.
15. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995;102(5):401-6.
16. Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid. Acta Obstet Gynecol Scand. 1967;46:572-80.
17. Vermylen J, Verhaegen-Declercq ML, Verstraete M, Fierens F. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb Diath Haemorrh. 1968;20(3):583-7.
18. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynecol. 1983;90(1):78-83.
19. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996;313(7057):579-82.
20. Westrom L, Bengtsson LP. Effect of tranexamic acid (AMCA) in menorrhagia with intrauterine contraceptive devices. J Reprod Med. 1970;5(4):41-8.
21. Rivera R, Wheeler RG, Balogh SA, Hernandez AB, Arreola M. Sustained intrauterine release of AMCA to reduce menstrual blood loss. Contracept Deliv Syst. 1984;5(2):109-15.
22. Ragab MI, Thomas MN. The use of tranexamic acid (AMCA) in IUDs as an anti-bleeding agent. Int J Gynaecol Obstet. 1976;14(2):137-41.
23. Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG. 2000;107(3):320-2.
24. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol. 1995;85(6):977-82.
25. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest. 1964;16:244-8.